Stock FOXW.U FOXWAYNE ENTERPRISES ACQUISITION CORP.
Add to a list
To use this feature you must be a member
Log inSign up
Inactive Instrument

Highlights FoxWayne Enterprises Acquisition Corp. Nasdaq

Equities

FOXW.U

US35166L2088

Highlights

Search
See the results
Unlock all the news: Be the first to know and act before the market!
100% Free Registration
Clover Inc. cancelled the acquisition of FoxWayne Enterprises Acquisition Corp. from a group of shareholders in a reverse merger transaction.
CI
FoxWayne Enterprises Acquisition Corp. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022
CI
Clover Inc. entered into a definitive business combination agreement to acquire FoxWayne Enterprises Acquisition Corp. from a group of shareholders for approximately $160 million in a reverse merger transaction.
CI
FoxWayne Enterprises Acquisition Corp. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022
CI
FoxWayne Enterprises Acquisition : Audited Balance Sheet as of January 22, 2021 (as restated) - Form 8-K/A
PU
FOXWAYNE ENTERPRISES ACQUISITION CORP. Other Events, Financial Statements and Exhibits (form 8-K/A)
AQ
FoxWayne Enterprises Acquisition Corp. Reports Earnings Results for the First Quarter Ended March 31, 2022
CI
FoxWayne Enterprises Acquisition Corp. Reports Earnings Results for the Full Year Ended December 31, 2021
CI
FoxWayne Enterprises Acquisition : Aerami Therapeutics Holdings, Inc. and FoxWayne Enterprises Acquisition Corp. Mutually Agree to Terminate Business Combination Agreement - Form 8-K
PU
Aerami Therapeutics Holdings, Inc. and FoxWayne Enterprises Acquisition Corp. Mutually Agree to Terminate Business Combination Agreement
PR
Aerami Therapeutics Holdings, Inc. cancelled the acquisition of FoxWayne Enterprises Acquisition Corp. from FoxWayne Enterprises Acquisition Sponsor LLC and others in a reverse merger transaction.
CI
FoxWayne Enterprises Acquisition : Amendment to Quarterly Report (Form 10-Q/A)
PU
FoxWayne Enterprises Acquisition : Innovative Inhaled Drug Delivery Developer Aerami Therapeutics to Merge with Special Purpose Acquisition Company FoxWayne Enterprises Acquisition Corp. to Become Public Company - Form 8-K
PU
Aerami Therapeutics to Go Public Via Merger with Blank-Check Firm FoxWayne Enterprises
MT
FOXWAYNE ENTERPRISES ACQUISITION CORP. : Non-Reliance on Previous Financials, Audits or Interim Review, Financial Statements and Exhibits (form 8-K)
AQ
FoxWayne Enterprises Acquisition Corp. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2021
CI
Foxwayne Enterprises Acquisition Corp. Reports Earnings Results for the Second Quarter Ended June 30, 2021
CI
Aerami Therapeutics Holdings, Inc. executed a non-binding letter of intent to acquire FoxWayne Enterprises Acquisition Corp. from FoxWayne Enterprises Acquisition Sponsor LLC and others for approximately $250 million in a reverse merger transaction.
CI
Foxwayne Enterprises Acquisition Corp. Reports Earnings Results for the First Quarter Ended March 31, 2021
CI
Foxwayne Enterprises Acquisition Corp. Reports Earnings Results for the Fourth Quarter Ended December 31, 2020
CI
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. FOXW Stock
  4. FOXW.U Stock
  5. News FoxWayne Enterprises Acquisition Corp.
  6. Highlights